US EditionPublished • loading... • Updated
Novo Nordisk cuts price of weight-loss drug Wegovy in China
Novo Nordisk halved Wegovy prices in Chinese provinces like Yunnan and Sichuan to lower patient costs and counter generic competition before semaglutide patent expires in March.
- Bloomberg reported on Monday that Novo Nordisk A/S slashed Wegovy list prices by about 50% in parts of China, with procurement documents and JD.com listings showing doses priced as low as $141.
- With the patent due to expire in March, analysts said the new prices could set the benchmark for semaglutide generics expected next quarter.
- Product details show Wegovy pen format includes four weekly doses, with Reuters reporting monthly prices in India at 8,800, 10,170, and 11,175 rupees; India is the second-largest market for type 2 diabetes.
- Novo said the cuts aim to ease patient costs and support treatment adherence, while Novo Nordisk shares were down 1.35% on Monday as Eli Lilly plans to invest over $1 billion in India.
- Contracting with local firms will support Eli Lilly's plans to produce complex drugs in India, while food companies adjusting menus reflect broader effects of growing GLP-1 drugs and users.
Insights by Ground AI
13 Articles
13 Articles
Novo Nordisk cuts price of weight-loss drug Wegovy in China
Novo Nordisk is lowering prices of its top-selling obesity drug Wegovy in China, the Danish drugmaker said on Monday, as it braces for intense competition from local rivals next year when the patent for its blockbuster treatment ends.
·United Kingdom
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left1Leaning Right1Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
13%
C 75%
12%
Factuality
To view factuality data please Upgrade to Premium
